Steven R. Schow, Ph.D., has served as Vice President, Research since March 2000, at Telik. He served as Senior Director of Medicinal Chemistry from March 1998 until March 2000. Prior to Telik, Dr. Schow served as a Director of Medicinal Chemistry at CV Therapeutics, Inc., a biotechnology company. He served as a Senior Group Leader at Lederle Laboratories, a division of American Cyanamid, from November 1991 until May 1995. Dr. Schow was a post-doctoral fellow in organic chemistry at the University of California at Los Angeles and the University of Pennsylvania. Dr. Schow holds a Ph.D. degree in organic chemistry from the University of California at San Diego and a B.S. degree in chemistry from California State University, Los Angeles. Currently, Dr. Schow serves as a consulting Professor, at the department of Chemical and Systems Biology, Stanford University, as an advisor for SPARK- Translational Research Program, and for the pharmaceutical industry.
Dr. Howard Maibach is an expert in contact and occupational dermatitis and sees patients at the Environmental Dermatosis Clinic, which is part of the Dermatology Clinic. His specialty is dermatotoxicology, or skin exposure toxicity; allergies and skin disorders; and dermatopharmacology or the study of medications for skin disorders. Dr. Maibach has been on the editorial board of more than 30 scientific journals and is a member of 19 professional societies including the American Academy of Dermatology, San Francisco Dermatological Society and the Internal Commission on Occupation Health. He is a professor in the Department of Dermatology at UCSF.
Scientific Board and Advisers
The director of the KU Protein Production Group, Dr. Philip,Gao, received his Ph. D. in Biochemistry at the University of Kansas in 1996. He has been working full time in research areas of molecular biology, production and biophysical characterization of proteins in the last 20 years. He has excellent background in protein purification, cell culture, molecular biology and fermentation and extensive experience in sample preparation of challenging proteins for enzymatic studies, NMR, X-ray crystallography, and Mass spectrometry. He equipped and managed a new membrane protein production facility from 2001-2007 in the National High Magnetic Field Laboratory at Florida State University and the COBRE protein production Core lab at University of Kansas from July 2008 to present. Both core facilities provide proteins used for team-based NIH projects to study structure and function of proteins. Dr. Gao oversees the operation of the laboratory, operates and maintains related laboratory equipment and participate in cloning, expression and protein purification experiments. He communicates with a variety of users, internal and external to devise appropriate strategies for each project. He prepares written reports of completed reports for clients and funding agencies.
Professor of Medicine, Microbiology and Immunology, Associate Director, Stanford Institute for Immunology, Transplantation and Infectious Diseases, Associate Dean, Office of Academic Affairs, School of Medicine, Senior Fellow, Woods Institute for the Environment, Attending Physician, Stanford University Medical Center.
Sharon Lake is CEO and Managing Director of OE Co, LLC. With 25 years of experience, Ms. Lake’s extensive entrepreneurial background and strong operational experience provides a comprehensive skill set to successfully lead a business. She has been a member on the founding team of over 15 MedTech start-ups – 6 of which, to date, were acquired for a combined value of over $400M and the remaining are still active. Over the course of her career, Ms. Lake has served as a CEO, General Manager, and executive in Business Development, Operations, and R&D. For 8 years she was an executive at InCube Labs, a medical device incubator and has held positions in engineering, marketing and operations at Guidant and Medtronic. Ms. Lake contributed intellectual property to a number of start-ups and is a named inventor on over 30 patents. Currently, she sits on the boards of CutaGenesis, RMx and Bowman International School. She received her Bachelor of Science degree in Mechanical Engineering from the University of Illinois.
Noga Qvit-Raz, PhD, is interested in the links between health and environmental parameters, focusing on the nexus of microbial biodiversity, a-biotic environmental parameters such as stress factors and human health. She is dedicated to the research and development of biological based UV protection approach, bringing her expertise and knowledge to manage the bridge between scientific innovations to consumer product. Prior to founding TopgeniX, she worked for over 12 years in the fields of microbiology, microbial ecology, environmental studies, biofilms, microbial communities characterizations, biodiversity, 16S rDNA analysis, single cell genomics, clinical microbiology, microbiome, high throughput data analysis, and molecular biology. Her work in these fields brought her to the conceptualization of a microbial sunscreen alternative. Noga has brought TopgeniX from concept, through seed fundraising, developing IP strategy, and breakthrough scientific technologies, to the next level of product development.
Meet Our Team
Jon Gasson is an experienced executive providing consulting services to medical technology companies, entrepreneurs and venture capital firms in the areas of company formation, fundraising, product development strategy, technology assessment, marketing, and business development. Jon has 21 years of medical technology experience. He has served as a senior manager in venture backed and large public companies. He was previously the President of Invuity, Inc., (IPO: 2015) a less invasive surgery company backed by Kleiner Perkins, InterWest Partners and private investors. He has also served in numerous business development, marketing and sales roles at Guidant, AVE and Medtronic. Jon holds a BA in Finance from the University of Florida and an MBA from Northwestern University’s J.L. Kellogg School of Management..
Dr. Brown is President of Valent Technologies, LLC. He is a serial entrepreneur in the drug development space. He co-founded Matrix Pharmaceuticals in 1985, which was acquired by Chiron. He also founded ChemGenex Therapeutics in 1999, which merged with a publicly traded Australian company in 2004 to become ChemGenex Pharmaceuticals, which was acquired Cephalon which was subsequently acquired by Teva. His most recent venture, Valent Technologies, LLC., has supported the development of several companies including Del Mar Pharmaceuticals and NewGen Therapeutics. Dr. Brown has 34 issued US patents and applications, many with foreign counterparts.